Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
NCT06570915 · Institute of Hematology & Blood Diseases Hospital, China · PHASE2 · withdrawn · last registry update 2026-05-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No eligeble patients” | – | Registry record, Institute of Hematology & Blood Diseases Hospital, China |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD38 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Results posted on the registry: Mayo Clinic, Carfilzomib + Daratumumab (NCT05497804)
- 2026-11-02Phase 3 first posted: Keymed Biosciences Co.Ltd, CM336 + CM313 (NCT07910903)
- 2026-10-29Phase 3 first posted: Janssen Research & Development, LLC, Ramantamig + Daratumumab (NCT07903272)
- 2026-10-29Phase 3 first posted: Kite, A Gilead Company, Anitocabtagene Autoleucel + Isatuximab (NCT07903506)
- 2026-10-28Phase 3 first posted: Regeneron Pharmaceuticals, Linvoseltamab + Daratumumab (NCT07901725)
- 2026-10-22Also stopped (withdrawn): City of Hope Medical Center, Bortezomib + Daratumumab (NCT03591744)
- 2026-10-22Phase 3 first posted: Alliance for Clinical Trials in Oncology, Daratumumab and Recombinant Human Hyaluronidase + Lenalidomide (NCT07887984)
- 2026-10-21Phase 3 first posted: Kite, A Gilead Company, Anitocabtagene autoleucel + Daratumumab (NCT07887672)
- 2026-09-29Results posted on the registry: Hoffmann-La Roche, Forimtamig + Carfilzomib (NCT06055075)
- 2026-09-29Also stopped (terminated): Hoffmann-La Roche, Forimtamig + Carfilzomib (NCT06055075)
- 2026-09-15Results posted on the registry: Academic and Community Cancer Research United, Carfilzomib + Daratumumab (NCT04756401)
- 2026-09-11Also stopped (withdrawn): Fred Hutchinson Cancer Center, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 + Cyclophosphamide (NCT04579523)
- 2026-08-28Phase 3 first posted: AbbVie, Etentamig + Daratumumab (NCT07793422)
- 2026-08-19Phase 3 first posted: CellCentric Ltd., InoPd + Investigator's choice of SAT (NCT07772024)
- 2026-08-14Phase 3 first posted: AstraZeneca, AZD0120 + Daratumumab (NCT07764978)
- 2026-08-03Phase 3 first posted: Biocad, BCD-248 + daratumumab + Daratumumab + pomalidomide + dexamethasone (NCT07742215)
- 2026-07-31Phase 3 first posted: Polish Myeloma Consortium, Teclistamab + Talquetamab (NCT07740486)
- 2026-07-29Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, Isatuximab + VRD (NCT07732712)
- 2026-07-28Results posted on the registry: University of Michigan Rogel Cancer Center, Daratumumab + Lenalidomide (NCT04140162)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-07-16Phase 3 first posted: Nexcella Inc., NXC-201 + Dara-CyBorD (NCT07709715)
- 2026-06-26Phase 3 first posted: University of Heidelberg Medical Center, Teclistamab + Daratumumab (NCT07671287)
- 2026-06-25Results posted on the registry: GlaxoSmithKline, Belantamab mafodotin + Isatuximab (NCT07217184)
- 2026-06-24Phase 3 first posted: Janssen Research & Development, LLC, Ramantamig + Daratumumab (NCT07665450)
- 2026-06-18Also stopped (withdrawn): Regeneron Pharmaceuticals, Linvoseltamab + Bortezomib (NCT07428369)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision